Biotech Values

[floblu14]

Canaccord Adams Maintains a 'Buy' on Momenta Pharmaceuticals (MNTA)

April 26, 2010 9:50 AM EDT

Canaccord Adams maintains a 'Buy' on Momenta Pharmaceuticals (Nasdaq: MNTA), price target $17

Canaccord analyst says, "Enoxaparin (M-Enox) is Momenta and partner Sandoz’s generic Lovenox (enoxaparin, or enox), Sanofi’s low molecular weight heparin, a complex mixed sugar chain drug. We expected approval of M-Enox in Q1/10, but still think approval is near. We do not think timing reflects FDA concerns around M-Enox efficacy or safety."

To see all the upgrades/downgrades on shares of MNTA, visit our Analyst Ratings page.

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules.

http://www.streetinsider.com/Analyst+Comments/Canaccord+Adams+Maintains+a+Buy+on+Momenta+Pharmaceuticals+(MNTA)/5561279.html